Tech Company Financing Transactions

STORM Therapeutics Funding Round

STORM Therapeutics, operating out of Cambridge, received $30 million from M Ventures, Pfizer Venture Investments and Cambridge Innovation Capital.

Transaction Overview

Company Name
STORM Therapeutics
Announced On
12/14/2022
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors

M Ventures (Lead Investor)

Pfizer Venture Investments (Lead Investor)

Cambridge Innovation Capital

Fast Track Initiative

IP Group

Seroba Life Sciences

Taiho Ventures (Sakae Asanuma)

UTokyo Innovation Platform

Proceeds Purpose
The company intends to use the funds to further expand its novel discovery platform to create additional products targeting RNA modification. The proceeds will advance Storm's potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias and will further expand its novel discovery platform to create additional products targeting RNA modification.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Babraham Research Campus Moneta Building
Cambridge, CB22 3AT
UK
Phone
+44 (0)1223 804174
Website
www.stormtherapeutics.com
Email Address
[email protected]
Overview
STORM Therapeutics is a University of Cambridge spin-out, translating the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.
Profile
STORM Therapeutics LinkedIn Company Profile
Social Media
STORM Therapeutics Company Twitter Account
Company News
STORM Therapeutics News
Facebook
STORM Therapeutics on Facebook
YouTube
STORM Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Keith Blundy
  Keith Blundy LinkedIn Profile  Keith Blundy Twitter Account  Keith Blundy News  Keith Blundy on Facebook
Chief Scientific Officer
Oliver Rausch
  Oliver Rausch LinkedIn Profile  Oliver Rausch Twitter Account  Oliver Rausch News  Oliver Rausch on Facebook
Vice President
Wesley Blackaby
  Wesley Blackaby LinkedIn Profile  Wesley Blackaby Twitter Account  Wesley Blackaby News  Wesley Blackaby on Facebook
VP - Bus. Development
David Simmons
  David Simmons LinkedIn Profile  David Simmons Twitter Account  David Simmons News  David Simmons on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/14/2022: Sparrow venture capital transaction
Next: 12/14/2022: LexCheck venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.